share_log

Oppenheimer Initiates Coverage On Sagimet Biosciences With Outperform Rating, Announces Price Target of $30

Benzinga ·  Dec 6, 2024 20:16  · Ratings

Oppenheimer analyst Jay Olson initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Outperform rating and announces Price Target of $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment